31 results
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
25 Oct 22
Report of Foreign Private Issuer
7:08am
for patient enrolment and will recruit patients in Israel, the U.S., and five countries in Europe. If the study achieves its endpoint, the Company
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
23 Aug 22
Can-Fite’s Drug Namodenoson Approved for Compassionate Use Treatment of Advanced Liver
7:13am
and will recruit patients in Israel, the U.S., and five countries in Europe. This pivotal study received a ‘green light’ to proceed from the U.S. Food
6-K
EX-99.1
ftq5661iyyk3e1we
13 Feb 20
Notice of Special General Meeting of Shareholders
4:30pm
424B4
xkhrf9n z33
12 Feb 20
Prospectus supplement with pricing info
6:46am
F-1/A
jciuf4r9p2wo cv5n
3 Feb 20
Registration statement (foreign) (amended)
5:31pm
F-1
pwdmgf
24 Jan 20
Registration statement (foreign)
4:40pm
6-K
EX-99.1
p8246bli3 1lqxl0b1y
9 Jan 20
Notice of Special General Meeting of Shareholders
4:41pm
20-F/A
r0uaq52yctbag2
2 Apr 19
Annual report (foreign) (amended)
6:52am
424B3
90mj kjs4
22 Mar 19
Prospectus supplement
4:50pm
F-1/A
amnohd1ixue wclqmgvd
12 Mar 19
Registration statement (foreign) (amended)
4:20pm
F-1
6tg1y925scyl b45
15 Feb 19
Registration statement (foreign)
4:32pm